Covered recipient · General Payments record
VIPIN GUPTA
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$907.24
55 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $907.24 | 55 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $432.85 | 28 |
| ABBVIE INC. | $177.99 | 12 |
| PFIZER INC. | $73.56 | 3 |
| Celgene Corporation | $57.49 | 3 |
| Janssen Biotech, Inc. | $39.47 | 2 |
| Merck Sharp & Dohme LLC | $37.64 | 2 |
| Ironwood Pharmaceuticals, Inc | $33.93 | 2 |
| Gilead Sciences, Inc. | $33.31 | 2 |
| Ardelyx, Inc. | $21.00 | 1 |
Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
VIPIN GUPTA
NPI 1912091794 · CMS profile ID 1243035
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
LIGHTHOUSE POINT, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1912091794?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- VIPIN GUPTA, NPI 1912091794, CMS profile ID 1243035. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1912091794?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). VIPIN GUPTA, NPI 1912091794, CMS profile ID 1243035. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1912091794?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- VIPIN GUPTA, NPI 1912091794, CMS profile ID 1243035, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1912091794?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
55 matching records · $907.24 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–55 of 55.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | $16.64 | 03/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025941775 | CMS |
| ABBVIE INC. | $14.87 | 02/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997407639 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.22 | 02/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057164235 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $11.51 | 01/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057204707 | CMS |
| ABBVIE INC. | $18.89 | 01/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997407637 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $926.87 | 11 |
| PY2025 | Principal investigator | $64,651.50 | 9 |
| PY2024 | Principal investigator | $120,677.23 | 9 |
| PY2023 | Principal investigator | $38,709.73 | 4 |
| PY2022 | Principal investigator | $11,502.32 | 4 |
| PY2021 | Recipient | $4,620.00 | 1 |
| PY2021 | Principal investigator | $32,072.27 | 15 |
| PY2020 | Principal investigator | $190,757.14 | 39 |
| PY2019 | Principal investigator | $106,043.75 | 11 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
20 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,892.00 | 11/12/2025 | Non-covered Recipient Entity Alliance Medical Research, Llc | A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1226096977 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,268.00 | 10/15/2025 | Non-covered Recipient Entity Alliance Medical Research, Llc | A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1226096982 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,475.00 | 10/15/2025 | Non-covered Recipient Entity Alliance Medical Research, Llc | A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1226096990 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $4,500.00 | 10/08/2025 | Non-covered Recipient Entity Alliance Medical Research Llc | An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice | No dispute reported | 06/30/2026 | 1235999121 |
| Recipient | Eli Lilly and Company | $388.40 | 10/07/2025 | Covered Recipient Physician | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1187873165 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,407.00 | 08/06/2025 | Non-covered Recipient Entity Alliance Medical Research, Llc | A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease | No dispute reported | 06/30/2026 | 1226096877 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13,891.00 | 07/30/2025 | Non-covered Recipient Entity Alliance Medical Research, Llc | A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1226096896 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,677.07 | 07/28/2025 | Non-covered Recipient Entity Accellacare - Sherman Oaks | A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease | No dispute reported | 06/30/2026 | 1235999399 |
| Recipient | SANOFI US SERVICES INC. | $30.00 | 07/18/2025 | Covered Recipient Physician | A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1226132938 |
| Recipient | SANOFI US SERVICES INC. | $30.00 | 07/18/2025 | Covered Recipient Physician | A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease | No dispute reported | 06/30/2026 | 1226132943 |
| Recipient | SANOFI US SERVICES INC. | $31.45 | 07/18/2025 | Covered Recipient Physician | A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1226132946 |
| Recipient | SANOFI US SERVICES INC. | $31.45 | 07/18/2025 | Covered Recipient Physician | A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease | No dispute reported | 06/30/2026 | 1226132950 |
| Recipient | SANOFI US SERVICES INC. | $30.00 | 07/18/2025 | Covered Recipient Physician | A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1226132954 |
| Recipient | SANOFI US SERVICES INC. | $30.00 | 07/18/2025 | Covered Recipient Physician | A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease | No dispute reported | 06/30/2026 | 1226132958 |
| Recipient | SANOFI US SERVICES INC. | $146.34 | 07/18/2025 | Covered Recipient Physician | A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1226132961 |
| Recipient | SANOFI US SERVICES INC. | $146.33 | 07/18/2025 | Covered Recipient Physician | A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease | No dispute reported | 06/30/2026 | 1226132966 |
| Recipient | SANOFI US SERVICES INC. | $31.45 | 07/18/2025 | Covered Recipient Physician | A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1226132970 |
| Recipient | SANOFI US SERVICES INC. | $31.45 | 07/18/2025 | Covered Recipient Physician | A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease | No dispute reported | 06/30/2026 | 1226132975 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $4,927.85 | 06/25/2025 | Non-covered Recipient Entity Velocity Clinical Research Blue Ash | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease | No dispute reported | 06/30/2026 | 1235991977 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,613.58 | 01/27/2025 | Covered Recipient Teaching Hospital Montefiore Medical Center | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). | No dispute reported | 06/30/2026 | 1236000548 |